An open-label, randomized, three-parallel-group study on pharmacodynamic effects of 8-week QD treatment with lixisenatide compared to liraglutide in patients with type 2 diabetes not adequately controlled with insulin glargine with or without metformin.

Trial Profile

An open-label, randomized, three-parallel-group study on pharmacodynamic effects of 8-week QD treatment with lixisenatide compared to liraglutide in patients with type 2 diabetes not adequately controlled with insulin glargine with or without metformin.

Completed
Phase of Trial: Phase II

Latest Information Update: 18 Oct 2016

At a glance

  • Drugs Lixisenatide (Primary) ; Liraglutide
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Sponsors Sanofi
  • Most Recent Events

    • 17 Sep 2014 Primary endpoint has been met (change from baseline for area under the plasma glucose concentration time profile), according to results presented at the 50th Annual Meeting of the European Association for the Study of Diabetes.
    • 17 Sep 2014 Results presented at the 50th Annual Meeting of the European Association for the Study of Diabetes.
    • 15 Sep 2014 Results presented at the 50th Annual Meeting of the European Association for the Study of Diabetes.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top